Sand Hill Angels- Portfolio-BiParSciences.png


BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors.

BiPar has raised around $60 million in VC funding, from firms like Domain Associates, Canaan Partners, Vulcan Capital, PolyTechnos Venture Partners, Asset Management Company, and Quantum Technology Partners. It also has raised venture debt from Lighthouse Capital Partners.

On April 15th, 2009, French drug maker Sanofi-Aventis S.A. announced it was acquiring BiPar Sciences for up to $500 million.

More Information